Addex Pharmaceuticals SA and Merck, Sharp and Dohme Research Ltd, an affiliate of Merck & Co, have entered into an exclusive collaboration and licensing agreement to develop a new class of ingested drugs that potentially will treat Parkinson’s disease and other diseases.
